Cizzle Biotech Make Breakthrough in Automating Test Results for Early Detection of Lung Cancer #ciz

StockBox

10.8K subscribers

ShareSubscribe

Cizzle Biotech's CEO, Allan Syms, discusses the company's expansion of its research program in partnership with the University of York following a pivotal breakthrough in the commercialization of the testing process to a platform that automates the testing process. The collaboration aims to develop biomarker technology (CIZ 1B) for early-stage cancer diagnosis, specifically targeting lung cancer. By Mark Fairbairn